{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:09:47Z","timestamp":1761293387272},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma is a plasma cell neoplasm with an extremely variable clinical course. Animal models are needed to better understand its pathophysiology and for preclinical testing of potential therapeutic agents. Hematopoietic cells expressing the hypermorphic <jats:italic>Rad50<\/jats:italic><jats:sup><jats:italic>s<\/jats:italic><\/jats:sup> allele show hematopoietic failure, which can be mitigated by the lack of a transcription factor, Mef\/Elf4. However, we find that 70% of <jats:italic>Mef<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup><jats:italic>Rad50<\/jats:italic><jats:sup><jats:italic>s\/s<\/jats:italic><\/jats:sup> mice die from multiple myeloma or other plasma cell neoplasms. These mice initially show an abnormal plasma cell proliferation and monoclonal protein production, and then develop anemia and a decreased bone mineral density. Tumor cells can be serially transplanted and according to array CGH and whole exome sequencing, the pathogenesis of plasma cell neoplasms in these mice is not linked to activation of a specific oncogene, or inactivation of a specific tumor suppressor. This model recapitulates the systemic manifestations of human plasma cell neoplasms, and implicates cooperativity between the <jats:italic>Rad50<\/jats:italic><jats:sup><jats:italic>s<\/jats:italic><\/jats:sup> and Mef\/Elf4 pathways in initiating myelomagenic mutations that promote plasma cell transformation.<\/jats:p>","DOI":"10.1038\/srep22760","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T10:04:26Z","timestamp":1457604266000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms"],"prefix":"10.1038","volume":"6","author":[{"given":"Takashi","family":"Asai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan A.","family":"Hatlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Ndiaye-Lobry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Deblasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fleisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena M.","family":"Cortizas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramiro E.","family":"Verdun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"BFsrep22760_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N Engl J Med 364, 1046\u201360 (2011).","journal-title":"N Engl J Med"},{"key":"BFsrep22760_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird, J. M. et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 154, 32\u201375 (2011).","journal-title":"Br J Haematol."},{"key":"BFsrep22760_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.hoc.2007.08.003","volume":"21","author":"CS Mitsiades","year":"2007","unstructured":"Mitsiades, C. S., Anderson, K. C. & Carrasco, D. R. Mouse models of human myeloma. Hematol Oncol Clin North Am. 21, 1051\u201369, viii (2007).","journal-title":"Hematol Oncol Clin North Am."},{"key":"BFsrep22760_CR4","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","volume":"92","author":"S Yaccoby","year":"1998","unstructured":"Yaccoby, S., Barlogie, B. & Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908\u201313 (1998).","journal-title":"Blood"},{"key":"BFsrep22760_CR5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V95.3.1056.003k26_1056_1065","volume":"95","author":"LM Pilarski","year":"2000","unstructured":"Pilarski, L. M. et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95, 1056\u201365 (2000).","journal-title":"Blood"},{"key":"BFsrep22760_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.thj.6200052","volume":"1","author":"K Asosingh","year":"2000","unstructured":"Asosingh, K., Radl, J., Van Riet, I., Van Camp, B. & Vanderkerken, K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 1, 351\u20136 (2000).","journal-title":"Hematol J"},{"key":"BFsrep22760_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","volume":"11","author":"DR Carrasco","year":"2007","unstructured":"Carrasco, D. R. et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349\u201360 (2007).","journal-title":"Cancer Cell"},{"key":"BFsrep22760_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","volume":"13","author":"M Chesi","year":"2008","unstructured":"Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167\u201380 (2008).","journal-title":"Cancer Cell"},{"key":"BFsrep22760_CR9","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1038\/emboj.2012.227","volume":"31","author":"C Vicente-Duenas","year":"2012","unstructured":"Vicente-Duenas, C. et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 31, 3704\u201317 (2012).","journal-title":"EMBO J"},{"key":"BFsrep22760_CR10","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188","volume":"122","author":"WM Kuehl","year":"2012","unstructured":"Kuehl, W. M. & Bergsagel, P. L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 122, 3456\u201363 (2012).","journal-title":"J Clin Invest"},{"key":"BFsrep22760_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature06168","volume":"449","author":"B Corneo","year":"2007","unstructured":"Corneo, B. et al. Rag mutations reveal robust alternative end joining. Nature 449, 483\u20136 (2007).","journal-title":"Nature"},{"key":"BFsrep22760_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nature06020","volume":"449","author":"CT Yan","year":"2007","unstructured":"Yan, C. T. et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 449, 478\u201382 (2007).","journal-title":"Nature"},{"key":"BFsrep22760_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm3047","volume":"12","author":"TH Stracker","year":"2011","unstructured":"Stracker, T. H. & Petrini, J. H. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 12, 90\u2013103 (2011).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFsrep22760_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nsmb.1639","volume":"16","author":"M Dinkelmann","year":"2009","unstructured":"Dinkelmann, M. et al. Multiple functions of MRN in end-joining pathways during isotype class switching. Nat Struct Mol Biol 16, 808\u201313 (2009).","journal-title":"Nat Struct Mol Biol"},{"key":"BFsrep22760_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ni1215","volume":"6","author":"M Yabuki","year":"2005","unstructured":"Yabuki, M., Fujii, M. M. & Maizels, N. The MRE11-RAD50-NBS1 complex accelerates somatic hypermutation and gene conversion of immunoglobulin variable regions. Nat Immunol 6, 730\u20136 (2005).","journal-title":"Nat Immunol"},{"key":"BFsrep22760_CR16","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1080\/10428190600909743","volume":"47","author":"S Rollinson","year":"2006","unstructured":"Rollinson, S., Kesby, H. & Morgan, G. J. Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 47, 2567\u201383 (2006).","journal-title":"Leuk Lymphoma"},{"key":"BFsrep22760_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2350-10-117","volume":"10","author":"JM Schuetz","year":"2009","unstructured":"Schuetz, J. M. et al. Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. BMC Med Genet 10, 117 (2009).","journal-title":"BMC Med Genet"},{"key":"BFsrep22760_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mrfmmm.2008.10.019","volume":"660","author":"C Yang","year":"2009","unstructured":"Yang, C., Betti, C., Singh, S., Toor, A. & Vaughan, A. Impaired NHEJ function in multiple myeloma. Mutat Res 660, 66\u201373 (2009).","journal-title":"Mutat Res"},{"key":"BFsrep22760_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u201372 (2011).","journal-title":"Nature"},{"key":"BFsrep22760_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2141.2010.08088.x","volume":"149","author":"PL Roddam","year":"2010","unstructured":"Roddam, P. L. et al. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol 149, 258\u201362 (2010).","journal-title":"Br J Haematol"},{"key":"BFsrep22760_CR21","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1101\/gad.1007902","volume":"16","author":"CF Bender","year":"2002","unstructured":"Bender, C. F. et al. Cancer predisposition and hematopoietic failure in Rad50(S\/S) mice. Genes Dev 16, 2237\u201351 (2002).","journal-title":"Genes Dev"},{"key":"BFsrep22760_CR22","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1101\/gad.1373705","volume":"19","author":"M Morales","year":"2005","unstructured":"Morales, M. et al. The Rad50S allele promotes ATM-dependent DNA damage responses and suppresses ATM deficiency: implications for the Mre11 complex as a DNA damage sensor. Genes Dev 19, 3043\u201354 (2005).","journal-title":"Genes Dev"},{"key":"BFsrep22760_CR23","first-page":"1721","volume":"13","author":"Y Miyazaki","year":"1996","unstructured":"Miyazaki, Y., Sun, X., Uchida, H., Zhang, J. & Nimer, S. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 13, 1721\u20139 (1996).","journal-title":"Oncogene"},{"key":"BFsrep22760_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.02.017","volume":"9","author":"HD Lacorazza","year":"2006","unstructured":"Lacorazza, H. D. et al. The transcription factor MEF\/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell 9, 175\u201387 (2006).","journal-title":"Cancer Cell"},{"key":"BFsrep22760_CR25","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/0008-5472.CAN-07-2355","volume":"68","author":"M Morales","year":"2008","unstructured":"Morales, M. et al. DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions. Cancer Res 68, 2186\u201393 (2008).","journal-title":"Cancer Res"},{"key":"BFsrep22760_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1074-7613(00)80319-2","volume":"5","author":"JR Gorman","year":"1996","unstructured":"Gorman, J. R. et al. The Ig(kappa) enhancer influences the ratio of Ig(kappa) versus Ig(lambda) B lymphocytes. Immunity 5, 241\u201352 (1996).","journal-title":"Immunity"},{"key":"BFsrep22760_CR27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","volume":"16","author":"E Terpos","year":"2005","unstructured":"Terpos, E. & Dimopoulos, M. A. Myeloma bone disease: pathophysiology and management. Ann Oncol 16, 1223\u201331 (2005).","journal-title":"Ann Oncol"},{"key":"BFsrep22760_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376\u201385 (2012).","journal-title":"Blood"},{"key":"BFsrep22760_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","volume":"68","author":"W Matsui","year":"2008","unstructured":"Matsui, W. et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68, 190\u20137 (2008).","journal-title":"Cancer Res"},{"key":"BFsrep22760_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1074-7613(02)00422-3","volume":"17","author":"HD Lacorazza","year":"2002","unstructured":"Lacorazza, H. D. et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17, 437\u201349 (2002).","journal-title":"Immunity"},{"key":"BFsrep22760_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","volume":"25","author":"WJ Chng","year":"2011","unstructured":"Chng, W. J. et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25, 1026\u201335 (2011).","journal-title":"Leukemia"},{"key":"BFsrep22760_CR32","first-page":"184","volume":"91","author":"C Largo","year":"2006","unstructured":"Largo, C. et al. Identification of overexpressed genes in frequently gained\/amplified chromosome regions in multiple myeloma. Haematologica 91, 184\u201391 (2006).","journal-title":"Haematologica"},{"key":"BFsrep22760_CR33","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","volume":"23","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. & Kuehl, W. M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23, 6333\u20138 (2005).","journal-title":"J Clin Oncol"},{"key":"BFsrep22760_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296\u2013303 (2005).","journal-title":"Blood"},{"key":"BFsrep22760_CR35","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan, F. et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99, 1745\u201357 (2002).","journal-title":"Blood"},{"key":"BFsrep22760_CR36","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692\u2013700 (2007).","journal-title":"Blood"},{"key":"BFsrep22760_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli, L. et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 48, 603\u201314 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFsrep22760_CR38","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354, 1362\u20139 (2006).","journal-title":"N Engl J Med"},{"key":"BFsrep22760_CR39","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek, R., Okubote, S. A. & Svachova, H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 163, 551\u201364 (2013).","journal-title":"Br J Haematol"},{"key":"BFsrep22760_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","volume":"102","author":"M Muramatsu","year":"2000","unstructured":"Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553\u201363 (2000).","journal-title":"Cell"},{"key":"BFsrep22760_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cell.2004.08.006","volume":"118","author":"AR Ramiro","year":"2004","unstructured":"Ramiro, A. R. et al. AID is required for c-myc\/IgH chromosome translocations in vivo . Cell 118, 431\u20138 (2004).","journal-title":"Cell"},{"key":"BFsrep22760_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","volume":"23","author":"LJ McHeyzer-Williams","year":"2005","unstructured":"McHeyzer-Williams, L. J. & McHeyzer-Williams, M. G. Antigen-specific memory B cell development. Annu Rev Immunol 23, 487\u2013513 (2005).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep22760_CR43","first-page":"6579","volume":"62","author":"Y Seki","year":"2002","unstructured":"Seki, Y. et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 62, 6579\u201386 (2002).","journal-title":"Cancer Res"},{"key":"BFsrep22760_CR44","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1038\/sj.onc.1210170","volume":"26","author":"JJ Yao","year":"2007","unstructured":"Yao, J. J. et al. Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26, 4032\u20137 (2007).","journal-title":"Oncogene"},{"key":"BFsrep22760_CR45","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1128\/MCB.01551-08","volume":"29","author":"G Sashida","year":"2009","unstructured":"Sashida, G. et al. ELF4\/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol 29, 3687\u201399 (2009).","journal-title":"Mol Cell Biol"},{"key":"BFsrep22760_CR46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.stem.2012.09.012","volume":"11","author":"E Bazzoli","year":"2012","unstructured":"Bazzoli, E. et al. MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 11, 836\u201344 (2012).","journal-title":"Cell Stem Cell"},{"key":"BFsrep22760_CR47","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1158\/0008-5472.CAN-11-0455","volume":"71","author":"G Sashida","year":"2011","unstructured":"Sashida, G. et al. The mef\/elf4 transcription factor fine tunes the DNA damage response. Cancer Res 71, 4857\u201365 (2011).","journal-title":"Cancer Res"},{"key":"BFsrep22760_CR48","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.celrep.2013.03.040","volume":"3","author":"L Chang","year":"2013","unstructured":"Chang, L., Guo, R., Huang, Q. & Yen, Y. Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms. Cell Rep 3, 1389\u201397 (2013).","journal-title":"Cell Rep"},{"key":"BFsrep22760_CR49","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1073\/pnas.022643999","volume":"99","author":"AL Kovalchuk","year":"2002","unstructured":"Kovalchuk, A. L. et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 99, 1509\u201314 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep22760_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.leu.2404067","volume":"20","author":"A Vacca","year":"2006","unstructured":"Vacca, A. & Ribatti, D. Bone marrow angiogenesis in multiple myeloma. Leukemia 20, 193\u20139 (2006).","journal-title":"Leukemia"},{"key":"BFsrep22760_CR51","first-page":"810","volume":"90","author":"K Asosingh","year":"2005","unstructured":"Asosingh, K. et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 90, 810\u20137 (2005).","journal-title":"Haematologica"},{"key":"BFsrep22760_CR52","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.dnarep.2005.08.004","volume":"4","author":"S Andersen","year":"2005","unstructured":"Andersen, S. et al. Monoclonal B-cell hyperplasia and leukocyte imbalance precede development of B-cell malignancies in uracil-DNA glycosylase deficient mice. DNA Repair (Amst) 4, 1432\u201341 (2005).","journal-title":"DNA Repair (Amst)"},{"key":"BFsrep22760_CR53","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1126\/science.1157533","volume":"321","author":"RA Keenan","year":"2008","unstructured":"Keenan, R. A. et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 321, 696\u20139 (2008).","journal-title":"Science"},{"key":"BFsrep22760_CR54","doi-asserted-by":"publisher","first-page":"W503","DOI":"10.1093\/nar\/gkn316","volume":"36","author":"X Brochet","year":"2008","unstructured":"Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36, W503\u20138 (2008).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep22760_CR55","first-page":"147","volume":"5","author":"XF Li","year":"2006","unstructured":"Li, X. F., Zanzonico, P., Ling, C. C. & O\u2019Donoghue, J. Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat 5, 147\u201355 (2006).","journal-title":"Technol Cancer Res Treat"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep22760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22760","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep22760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:06:47Z","timestamp":1672891607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep22760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3,31]]}},"alternative-id":["BFsrep22760"],"URL":"https:\/\/doi.org\/10.1038\/srep22760","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]},"assertion":[{"value":"10 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22760"}}